Search results for " Drug"

showing 10 items of 3138 documents

Granuloma anulare disseminatum als seltene Nebenwirkung von Allopurinol

1995

During long-term therapy of hyperuricaemia with allopurinol (300 mg/d) two patients developed generalized granuloma annulare. The diagnoses were confirmed by histology; concomitant diseases, especially diabetes mellitus, were not detectable. Following discontinuation of allopurinol therapy, cutaneous granulomas healed without relapse. Hyperuricaemia could be controlled by low-purine diet and medication avoiding allopurinol. The clinical history of our two patients suggested a causal connection between allopurinol therapy and generalized granuloma annulare. For this reason we rate the development of this disease in both cases as a rare but significant side effect of allopurinol. This should …

musculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyChemotherapySide effectbusiness.industrymedicine.medical_treatmentnutritional and metabolic diseasesAllopurinolDermatologymedicine.diseaseConcomitant drugDermatologyDiscontinuationGranulomaConcomitantmedicinebusinessmedicine.drugGeneralized granuloma annulareDer Hautarzt
researchProduct

Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?

2017

Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in active rheumatoid and psoriatic arthritis. “Oral ulcers” are reported in 3-5% of leflunomide medicated rheumatoid arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ulcer in the tongue of a rheumatoid arthritis patient managed with leflunomide and contemplate on its pathogenesis. Key words:Leflunomide, oral ulcer, DHODH.

musculoskeletal diseasesmedicine.medical_specialtyCase ReportOdontologíaDisease030207 dermatology & venereal diseases03 medical and health sciencesPsoriatic arthritis0302 clinical medicineTonguemedicineOral ulcersskin and connective tissue diseasesAdverse effectGeneral DentistryLeflunomide030203 arthritis & rheumatologyOral Medicine and Pathologybusiness.industry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludDermatology3. Good healthSurgerymedicine.anatomical_structureAdverse drug eventRheumatoid arthritisUNESCO::CIENCIAS MÉDICASbusinessmedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…

musculoskeletal diseasesmedicine.medical_treatmentImmunologyAnti-Inflammatory AgentsDrug Evaluation PreclinicalType II collagenArthritisInflammationPharmacologyAuto-immunity transplantation and immunotherapy [N4i 4]DinoprostoneGeneral Biochemistry Genetics and Molecular BiologyMiceRheumatologyOrganometallic CompoundsPerception and Action [DCN 1]medicineAnimalsImmunology and AllergyChronic inflammation and autoimmunity [UMCN 4.2]Dose-Response Relationship Drugbiologybusiness.industryRANK LigandInterleukinIntercellular Adhesion Molecule-1medicine.diseaseArthritis ExperimentalPathogenesis and modulation of inflammation [N4i 1]Cellular infiltrationCyclooxygenase 2Mice Inbred DBARANKLImmunologybiology.proteinCytokinesTumor necrosis factor alphaMicrobial pathogenesis and host defense [UMCN 4.1]Inflammation Mediatorsmedicine.symptombusinessInfection and autoimmunity [NCMLS 1]Heme Oxygenase-1Immunity infection and tissue repair [NCMLS 1]Prostaglandin E
researchProduct

Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis

2015

Although statins remain the cornerstone of lipid-lowering therapy for reducing the burden of atherosclerotic vascular disease, their administration has been associated with muscle-related adverse effects, including myalgia and rhabdomyolysis. Such adverse events are probably due to reduced antioxidant defenses associated with fewer intermediate metabolites in the cholesterol synthesis pathway. We hypothesize that the concomitant inhibition of xanthine oxidase via coadministration of allopurinol with statins could diminish reactive oxygen species (ROS)-related muscle damage, which would have in turn have positive effects on both the incidence of muscle-related adverse events and cardiovascul…

myalgiaXanthine OxidaseAntioxidantStatinUbiquinonemedicine.drug_classAllopurinolmedicine.medical_treatmentHypercholesterolemiaAllopurinolPharmacologyRhabdomyolysischemistry.chemical_compoundAnimalsHumansMedicineXanthine oxidaseEnzyme InhibitorsXanthine oxidaseAdverse effectchemistry.chemical_classificationReactive oxygen speciesLipid-lowering drugsbusiness.industryMyalgiamedicine.diseasechemistryCardiovascular DiseasesHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.symptomReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessRhabdomyolysisBiomarkersmedicine.drugAtherosclerosis
researchProduct

The Effect of Acetylsalicylic Acid, as a Representative Non-Steroidal Anti-Inflammatory Drug, on the Activity of Myeloperoxidase

2023

Background: Acetylsalicylic acid (ASA or aspirin) is one of the world’s most widely used non-steroidal anti-inflammatory drug (NSAID). Numerous studies have shown that the long-term use of aspirin may contribute to longer survival among patients with various types of cancer, including ovarian cancer. Aim: The aim of this study was to investigate the effect of ASA on myeloperoxidase (MPO), which is found at an elevated level in women with ovarian cancer, among others. Methods: The influence of different concentrations of ASA on the chlorinating and peroxidase activity of MPO was analysed. The relationship between the concentration of ASA and the degree of inhibition of MPO activity was deter…

myeloperoxidasenon-steroidal anti-inflammatory drugsacetylsalicylic acidPharmaceuticals
researchProduct

Preparation, characterization and biological evaluation of Nanostructured Lipid Carriers (NLCs) conteining sorafenib

2013

nanocarrier drug delivery
researchProduct

Polymeric Nanogels: Nanocarriers For Drug Delivery Application.

2012

The application of nanotechnology to medicine has enabled the development of functionalised nanoparticles that, acting as carriers, can be loaded with drugs or genetic material to be released with a controlled mechanism in specific districts of the organism. Even though nanomedicine is a relative new branch of science, many type of nanocarriers for drug delivery have been developed over the past 30 years, such as liposomes, dendrimers, quantum dots, solid lipid nanoparticles, viruses and virus-like nanoparticles as well as a wide var iety of polymeric nanoparticles. Among these last, in our opinion, nanogels deserve a special attention. Nanogels are nanoscalar polymer networks, with a tende…

nanocarriers drug deliverySettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

PREPARAZIONE E CARATTERIZZAZIONE DI NANOSISTEMI LIPIDICI PER IL DIREZIONAMENTO E IL RILASCIO MODIFICATO DI FARMACI E ACIDI NUCLEICI IN TERAPIA ONCOLO…

2016

sono stati sviluppati sistemi nanoparticellari in grado di intrappolare elevate quantità di farmaci e di legare materiale genico. I sistemi preparati sono stati caratterizzati da un punto di vista chimico-fisico e tecnologico farmaceutico. Sono stati infine utilizzati per prove in vitro e i risultati ottenuti hanno mostrato che essi possiedono le caratteristiche per potere essere considerati dei validi carrier per farmaci e materiale genico nel trattamento oncologico.

nanoparticelleterapia genicatumorecarcinoma ovariconanoparticelle; cancro; terapia genica; antitumorali; drug delivery; epatocarcinoma; carcinoma ovaricocaratterizzazioneSettore CHIM/09 - Farmaceutico Tecnologico Applicativodrug and gene deliverydrug deliverycancroantitumoraliepatocarcinoma
researchProduct

SUPERPARAMAGNETIC HYDROPHOBIC POLYASPARTAMIDE NANOPARTICLES FOR ANTICANCER DRUG DELIVERY

2012

nanoparticles PHEA drug delivery system anticancer drugSettore CHIM/09 - Farmaceutico Tecnologico Applicativo
researchProduct

Biocompatible Lipid Nanoparticles as Carriers to Improve Curcumin Efficacy in Ovarian Cancer Treatment

2017

Curcumin is a natural molecule with proved anticancer efficacy on several human cancer cell lines. However, its clinical application has been limited due to its poor bioavailability. Nanocarrier-based drug delivery approaches could make curcumin dispersible in aqueous media, thus overtaking the limits of its low solubility. The aim of this study was to increase the bioavailability and the antitumoral activity of curcumin, by entrapping it into nanostructured lipid carriers (NLCs). For this purpose here we describe the preparation and characterization of three kinds of curcumin-loaded NLCs. The nanosystems allowed the achievement of a controlled release of curcumin, the amounts of curcumin r…

nanostructured lipid carriers curcumin drug release cancer epithelial ovarian cellsCurcuminNanoparticleAdministration Oral02 engineering and technologyPharmacologynanostructured lipid carrier03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug Delivery SystemsNanoparticleSettore BIO/10 - BiochimicamedicineHumanscancerParticle SizeDrug Carrierdrug releaseCell ProliferationOvarian NeoplasmsDrug CarriersOvarian NeoplasmChemistry (all)General ChemistryLipid021001 nanoscience & nanotechnologyBiocompatible materialmedicine.diseaseControlled releaseLipidsBioavailabilitychemistryAgricultural and Biological Sciences (all)Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisDrug deliveryCurcuminNanoparticlesFemaleNanocarriers0210 nano-technologyGeneral Agricultural and Biological SciencesOvarian cancerDrug Delivery Systemepithelial ovarian cellHuman
researchProduct